Clinical Trial Update: Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Telisotuzumab Vedotin in combination with Osimertinib or standard-of-care chemotherapy for EGFR-mutant, MET-overexpressing non-small …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib (osimertinib)
• Standard of care chemotherapy
• Telisotuzumab Vedotin (Telisotuzumab Vedotin)

Snippet

Sponsor: AbbVie | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: WITHDRAWN